Hosted on MSN12h
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
Managed Healthcare Executive7h
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
PMLiVE17h
BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use
BeiGene’s Tevimbra (tislelizumab-jsgr) has been approved by the US Food and Drug Administration (FDA) as part of a first-line ...
FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction
BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development ...
Cure Today1d
FDA Approves Tevimbra Plus Chemotherapy For Some With Esophageal Cancer
The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
The Pharma Letter19h
New US approval for BeiGene’s Tevimbra
The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing ...
Monthly Prescribing Reference1d
Tevimbra Plus Chemotherapy Approved as First-Line Tx for Advanced Esophageal Cancer
The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...
BeiGene wins FDA nod for Tevimbra in first-line esophageal cancer
BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent ...
Medscape22h
Tislelizumab Receives First-Line Nod for Unresectable/Metastatic ESCC
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
BioSpace1d
BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...